Ezetimibe
Also known as: Zetia, Ezetrol
Cholesterol Absorption Inhibitor | Lipid Management On Cycle
Overview
Ezetimibe is a selective cholesterol absorption inhibitor that blocks the Niemann-Pick C1-Like 1 (NPC1L1) protein in the brush border of the small intestine, preventing dietary and biliary cholesterol from entering the bloodstream. Approved by the FDA in 2002, it occupies a unique niche among lipid-lowering agents by targeting intestinal cholesterol uptake rather than hepatic cholesterol synthesis. In the context of anabolic steroid use, ezetimibe has become a go-to ancillary compound for managing the dyslipidemia that accompanies many AAS cycles, particularly oral steroids like oxandrolone (Anavar) and stanozolol (Winstrol) that are notorious for crashing HDL cholesterol and elevating LDL. While statins remain the first-line treatment for hypercholesterolemia in the general population, ezetimibe is frequently used alone or stacked with a statin by steroid users seeking to mitigate cycle-induced lipid damage without adding yet another hepatotoxic compound to the mix.
Key benefits
- Reduces LDL cholesterol by 15-20% as monotherapy
- Complementary mechanism to statins allows additive LDL reduction of 25% when combined
- Minimal hepatotoxicity, making it suitable alongside hepatotoxic oral AAS
- Simple once-daily dosing with no titration required
- No significant impact on CoQ10 levels (unlike statins)
- Well tolerated with a side effect profile comparable to placebo in clinical trials
- Proven cardiovascular outcome benefit when added to statin therapy (IMPROVE-IT trial)
- Helps manage the severe lipid disruption caused by oral steroids like Anavar and Winstrol
Mechanism of action
Ezetimibe selectively inhibits the NPC1L1 transporter protein located on the luminal surface of enterocytes in the jejunum of the small intestine. NPC1L1 is the critical gateway for intestinal cholesterol absorption, responsible for uptaking both dietary cholesterol and the much larger pool of biliary cholesterol that is recirculated through the enterohepatic cycle. By blocking this transporter, ezetimibe reduces cholesterol delivery to the liver, which in turn upregulates hepatic LDL receptor expression to compensate for the reduced cholesterol supply. This upregulation increases LDL clearance from the bloodstream. The mechanism is entirely complementary to statins, which inhibit HMG-CoA reductase to reduce hepatic cholesterol synthesis. When the liver is deprived of cholesterol from both sources simultaneously, the LDL-lowering effect is significantly amplified. Ezetimibe undergoes glucuronidation in the intestinal wall and liver to form its active metabolite, ezetimibe-glucuronide, which is also pharmacologically active and participates in enterohepatic recirculation, contributing to the drug's prolonged duration of action.
Molecular data
- Type
- Azetidinone (C24H21F2NO3)
- Half-life
- ~22 hours
Indications
What the research community uses this compound for, with self-reported effectiveness.
Lipid Management
Cardiovascular Risk Reduction
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 10 mg/day | Once daily | — |
| — | 10 mg/day | Once daily, throughout cycle and into PCT | — |
| — | 10 mg/day ezetimibe + statin of choice | Once daily (ezetimibe can be taken same time as statin or separately) | — |
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Gastrointestinal discomfort (diarrhea, abdominal pain) - mild and infrequent, reported at similar rates to placebo
- Upper respiratory tract infection (reported in clinical trials but not clearly drug-related)
- Fatigue and headache (uncommon, typically transient)
Rare side effects
- Elevated liver transaminases (ALT/AST) - primarily seen when combined with a statin, rare with ezetimibe monotherapy
- Myalgia (muscle pain) - very rare with monotherapy, more common when combined with statins
- Hypersensitivity reactions including angioedema and rash (extremely rare)
- Pancreatitis (isolated case reports, causal relationship not established)
Contraindications
- Known hypersensitivity to ezetimibe or any component of the formulation
- Active liver disease or unexplained persistent elevations in hepatic transaminases (when combined with a statin)
- Pregnancy and breastfeeding (when used in combination with a statin)
Monitoring
- Lipid panel: at baseline, 4-6 weeks after initiation, then every 3-6 months (more frequently during AAS cycles)
- Liver function tests (ALT/AST): at baseline and as clinically indicated, especially when combined with a statin or hepatotoxic oral AAS
- Creatine kinase (CK): only if muscle symptoms develop
- For AAS users: comprehensive lipid panel at baseline, mid-cycle, end of cycle, and 4-8 weeks post-PCT
References
Primary literature and clinical-trial data informing this entry.